What is B. Riley’s Forecast for CAPR FY2025 Earnings?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities research analysts at B. Riley lowered their FY2025 earnings estimates for shares of Capricor Therapeutics in a research report issued to clients and investors on Tuesday, November 11th. B. Riley analyst M. El-Saadi now anticipates that the biotechnology company will post earnings of ($2.03) per share for the year, down from their prior forecast of ($1.85). The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Several other research firms have also issued reports on CAPR. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. Roth Capital boosted their price objective on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Capricor Therapeutics in a report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.38.

Capricor Therapeutics Stock Down 2.0%

Shares of NASDAQ CAPR traded down $0.11 during trading on Friday, reaching $5.66. 233,004 shares of the company traded hands, compared to its average volume of 1,831,244. The firm has a 50 day simple moving average of $6.54 and a 200-day simple moving average of $8.24. Capricor Therapeutics has a 52-week low of $5.43 and a 52-week high of $20.75. The stock has a market capitalization of $258.58 million, a PE ratio of -3.45 and a beta of 0.58.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.54).

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CAPR. Farther Finance Advisors LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at $28,000. Parkside Financial Bank & Trust bought a new position in shares of Capricor Therapeutics in the third quarter worth about $36,000. Russell Investments Group Ltd. grew its holdings in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 2,786 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after buying an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC bought a new stake in Capricor Therapeutics during the 3rd quarter valued at about $92,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.